SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19Онлайн
This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).
While the determinants of COVID-19 disease severity and EPCs are poorly understood, the varied clinical manifestations of COVID-19 have directed attention to the distribution of SARS-CoV-2 in the body. Although SARS-CoV-2 RNA is most concentrated in the nasopharynx, it has also been found in numerous other tissues, raising questions about dissemination of viral RNA throughout the body as well as the role of this process in disease severity and extrapulmonary complications. Recent studies have detected low levels of SARS-CoV-2 RNA in blood and have associated RNAemia with disease severity and biomarkers of dysregulated immune response.
In this webinar, Dr. Nikhil Ram Mohan, a postdoctoral scholar in the Department of Emergency Medicine at Stanford University, will discuss a study that used an array-based dPCR platform to detect and quantify SARS-CoV-2 RNA in specimens collected from the nasopharynx and from plasma of patients diagnosed with COVID-19.
He will discuss how variation in SARS-CoV-2 RNAemia may help explain disparities in disease severity and EPCs from COVID-19 as well as how using digital PCR to test for RNAemia early in the course of illness may help guide patient triage and management.